P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2026 Jun 17 [Epub ahead of print]
Patrick C Lee, Michael T Schweizer, Rosa Nadal
Fred Hutchinson Cancer Center Seattle, WA United States., Fred Hutchinson Cancer Center United States.